

Reference number(s)
1701-A

SPECIALTY GUIDELINE MANAGEMENT

BELEODAQ (belinostat)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- A. FDA-Approved Indication¹
Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
- B. Compendial Uses²
Non-Hodgkin's Lymphoma (NHL)
 - 1. Adult T-cell leukemia/lymphoma (ATLL)
 - 2. Mycosis fungoides (MF)/Sezary syndrome (SS)
 - 3. Primary cutaneous CD30+ T-cell lymphoproliferative disorders

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

- A. **Peripheral T-cell lymphoma (PTCL)**^{1,2}
Authorization of 12 months may be granted for treatment of PTCL.
- B. **Adult T-cell leukemia/lymphoma (ATLL)**²
Authorization of 12 months may be granted for treatment of ATLL.
- C. **Mycosis fungoides (MF)/Sezary syndrome (SS)**²
Authorization of 12 months may be granted for treatment of mycosis fungoides (MF)/Sezary syndrome (SS).
- D. **Primary cutaneous CD30+ T-cell lymphoproliferative disorders**²
Authorization of 12 months may be granted for treatment of cutaneous anaplastic large cell lymphoma (ALCL).

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

Reference number(s)
1701-A

IV. REFERENCES

1. Beleodaq [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc. April 2017.
2. The NCCN Drugs & Biologics Compendium® © 2018 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org> Accessed March 27, 2018.